Dr. Sartor Announces Bayer has Requested FDA Approval of Alpharedin & He Will Join Malecare to Make a Pod Cast Upon its Approval
On Thursday evening I had the opportunity to meet Dr. Oliver Sartor from the University of Tulane. At that time he informed me that Bayer had finally submitted the required paperwork to the FDA for [...]
On the Horizon – Cabozantinib for the Treatment of Bone Mets in Men with Advanced Prostate Cancer
According to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan men with advanced prostate cancer experienced significant and rapid positive effects from an investigational treatment known as cabozantinib. In a n [...]
Deciding Whether to Allow CPR in People with Advanced Cancer
It is unfortunate, but some of us will approach a time when we know that the advanced prostate cancer we have been battling has gotten the better of us and will end our life in [...]
Some Good Morning News, Zytiga Approved by the FDA for Earlier Use
Some mornings we just wake up to great news and today is one of those mornings. The Food and Drug Administration (FDA) has just announced that they have approved Zytiga (abiraterone acetate) for use prior [...]
Two New Sites Open for Early/Expanded Access to Radium-233 (Alapharedin) in Fort Meyers, FL. & Philadelphia, PA
The Early/Expanded Access Committee has been continuing to work on getting additional sites open for men with advanced prostate cancer to get access to the yet unapproved drug Radium-233 Chloride (Alapharadin). Due to the hard [...]
A New Trial Combining Provenge with A New Investigational Treatment to Enhance Survival
I have written much about the need to begin studies of both timing and combining of the many new treatments we have recently developed for the treatment of advanced prostate cancer. With the FDA approval [...]